Related references
Note: Only part of the references are listed.Pharmacokinetics of R- and S-Carvedilol in routinely treated Japanese patients with heart failure
Isao Horiuchi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis
Yoh Takekuma et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
Enantioselective and highly sensitive determination of carvedilol in human plasma and whole blood after administration of the racemate using normal-phase high-performance liquid chromatography
Masako Saito et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Multiple regression analysis of pharmaeogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers
M Honda et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2006)
Exchange of β-blockers in heart failure patients.: Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)
A Di Lenarda et al.
EUROPEAN JOURNAL OF HEART FAILURE (2005)
Evaluation of Bayesian estimation of pharmacokinetic parameters
S Tsuchiwata et al.
THERAPEUTIC DRUG MONITORING (2005)
Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial
M Hori et al.
AMERICAN HEART JOURNAL (2004)
Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure
D Tenero et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2000)
CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
Y Nishida et al.
PHARMACOGENETICS (2000)
Share Paper
